Published in Antimicrob Agents Chemother on July 01, 2005
Escherichia coli in Europe: an overview. Int J Environ Res Public Health (2013) 1.21
Filoviruses utilize glycosaminoglycans for their attachment to target cells. J Virol (2013) 1.11
Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules (2007) 1.05
Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. Antimicrob Agents Chemother (2012) 0.95
Exploiting dendrimer multivalency to combat emerging and re-emerging infectious diseases. Mol Pharm (2011) 0.95
A novel dendrimeric peptide with antimicrobial properties: structure-function analysis of SB056. Biophys J (2012) 0.90
Inhibition of herpes simplex virus type 1 and type 2 infections by peptide-derivatized dendrimers. Antimicrob Agents Chemother (2011) 0.88
Design and activity of a 'dual-targeted' antimicrobial peptide. Int J Antimicrob Agents (2009) 0.87
Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin Drug Discov (2007) 0.87
Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications. Front Microbiol (2011) 0.84
A peptide derived from phage display library exhibits antibacterial activity against E. coli and Pseudomonas aeruginosa. PLoS One (2013) 0.84
Clavanin bacterial sepsis control using a novel methacrylate nanocarrier. Int J Nanomedicine (2014) 0.83
Multivalent Antimicrobial Peptides as Therapeutics: Design Principles and Structural Diversities. Int J Pept Res Ther (2010) 0.83
Enhanced amphiphilic profile of a short β-stranded peptide improves its antimicrobial activity. PLoS One (2015) 0.82
Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interface Focus (2012) 0.82
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. PLoS One (2013) 0.82
Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front Pharmacol (2014) 0.81
Effects of dimerization on the structure and biological activity of antimicrobial peptide Ctx-Ha. Antimicrob Agents Chemother (2012) 0.81
The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. Antimicrob Agents Chemother (2011) 0.80
Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLoS One (2012) 0.80
In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Sci Rep (2016) 0.79
Novel method for selection of antimicrobial peptides from a phage display library by use of bacterial magnetic particles. Appl Environ Microbiol (2008) 0.78
Characterization of a branched lipopeptide candidate vaccine against influenza A/Puerto Rico 8/34 which is recognized by human B and T-cell immune responses. Virol J (2011) 0.77
Immunomodulatory and Anti-inflammatory Activity in Vitro and in Vivo of a Novel Antimicrobial Candidate. J Biol Chem (2016) 0.75
Antimicrobial peptides of multicellular organisms. Nature (2002) 23.50
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Searching for peptide ligands with an epitope library. Science (1990) 10.75
Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (1985) 10.42
Peptide antibiotics and their role in innate immunity. Annu Rev Immunol (1995) 6.81
Peptide antibiotics. Lancet (1997) 6.76
Peptide antibiotics. Antimicrob Agents Chemother (1999) 5.76
Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A (1988) 5.52
THE OSMOTIC RESISTANCE (FRAGILITY) OF HUMAN RED CELLS. J Clin Invest (1947) 5.00
Mode of action of membrane active antimicrobial peptides. Biopolymers (2002) 4.74
Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta (1999) 4.71
Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry (1999) 3.88
A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. J Biol Chem (1988) 2.70
Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett (2002) 2.44
Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem (2002) 2.02
Molecular recognition between membrane-spanning polypeptides. Trends Biochem Sci (1995) 1.98
Managing antibiotic resistance. N Engl J Med (2000) 1.90
Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord (2002) 1.89
Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem (1998) 1.83
Cationic antimicrobial peptides : issues for potential clinical use. BioDrugs (2003) 1.50
Interaction of antimicrobial peptides from Australian amphibians with lipid membranes. Chem Phys Lipids (2003) 1.23
Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem (2003) 1.20
Synthetic combinatorial libraries: novel discovery strategy for identification of antimicrobial agents. Antimicrob Agents Chemother (1996) 1.11
Antimicrobial dendrimeric peptides. Eur J Biochem (2002) 1.07
Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res (1991) 0.97
Structure-function relationships in novel peptide dodecamerswith broad-spectrum bactericidal and endotoxin-neutralizing activities. Biochem J (2000) 0.96
Rapid identification of compounds with enhanced antimicrobial activity by using conformationally defined combinatorial libraries. Biochem J (1996) 0.95
Rational design and molecular diversity for the construction of anti-alpha-bungarotoxin antidotes with high affinity and in vivo efficiency. Chem Biol (2003) 0.90
Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. FEBS Lett (2003) 0.89
Antibacterial activity of bactenecin 5 fragments and their interaction with phospholipid membranes. J Pept Sci (2001) 0.82
New reagents, reactions, and peptidomimetics for drug design. Biopolymers (2001) 0.81
CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother (2006) 6.58
Metallo-β-lactamases: a last frontier for β-lactams? Lancet Infect Dis (2011) 6.00
Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol (2002) 4.15
Replicon typing of plasmids encoding resistance to newer beta-lactams. Emerg Infect Dis (2006) 3.75
Molecular characterization of metallo-beta-lactamase-producing Acinetobacter baumannii and Acinetobacter genomospecies 3 from Korea: identification of two new integrons carrying the bla(VIM-2) gene cassettes. J Antimicrob Chemother (2002) 3.46
Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother (2005) 3.10
Independently evolving species in asexual bdelloid rotifers. PLoS Biol (2007) 3.05
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J Clin Microbiol (2002) 2.56
On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother (2003) 2.47
Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol (2003) 2.45
New species in the Old World: Europe as a frontier in biodiversity exploration, a test bed for 21st century taxonomy. PLoS One (2012) 2.32
Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa. J Clin Microbiol (2002) 2.21
Diagnosis of vascular graft infections with antibodies against staphylococcal slime antigens. Lancet (2002) 2.14
CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol (2013) 2.14
Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase. J Clin Microbiol (2002) 2.02
Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother (2004) 1.98
Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol (2009) 1.93
Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol (2006) 1.91
Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol (2009) 1.86
In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother (2013) 1.83
Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother (2007) 1.81
IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother (2003) 1.77
Clonal relatedness and conserved integron structures in epidemiologically unrelated Pseudomonas aeruginosa strains producing the VIM-1 metallo-{beta}-lactamase from different Italian hospitals. Antimicrob Agents Chemother (2005) 1.77
Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol (2006) 1.72
Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis (2009) 1.64
Characterization of pABVA01, a plasmid encoding the OXA-24 carbapenemase from Italian isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2009) 1.64
CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother (2006) 1.60
Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents (2005) 1.56
Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.55
Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J Clin Microbiol (2002) 1.54
CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother (2002) 1.52
AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp. Antimicrob Agents Chemother (2002) 1.51
High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J Infect Dis (2004) 1.48
Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase. J Clin Microbiol (2005) 1.45
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Detection of CTX-M-type beta-lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother (2004) 1.39
Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis (2005) 1.38
Persistent carriage and infection by multidrug-resistant Escherichia coli ST405 producing NDM-1 carbapenemase: report on the first Italian cases. J Clin Microbiol (2011) 1.38
Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy. J Clin Microbiol (2004) 1.37
Population structure and resistance genes in antibiotic-resistant bacteria from a remote community with minimal antibiotic exposure. Antimicrob Agents Chemother (2007) 1.36
Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-beta-lactamase: first Italian outbreak. J Antimicrob Chemother (2007) 1.36
Molecular characterization of integrons in epidemiologically unrelated clinical isolates of Acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays. Antimicrob Agents Chemother (2002) 1.36
The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem (2003) 1.35
Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia. Emerg Infect Dis (2006) 1.28
CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. Antimicrob Agents Chemother (2006) 1.28
Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-beta-lactamase determinants in European hospital. Emerg Infect Dis (2004) 1.27
Molecular evolution of metallo-beta-lactamase-producing Pseudomonas aeruginosa in a nosocomial setting of high-level endemicity. J Clin Microbiol (2006) 1.26
Tn5393d, a complex Tn5393 derivative carrying the PER-1 extended-spectrum beta-lactamase gene and other resistance determinants. Antimicrob Agents Chemother (2005) 1.24
FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob Agents Chemother (2012) 1.23
Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem (2003) 1.20
Escherichia coli from Italy producing OXA-48 carbapenemase encoded by a novel Tn1999 transposon derivative. Antimicrob Agents Chemother (2012) 1.17
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding. Antimicrob Agents Chemother (2010) 1.16
Prevalence and characterization of metallo-beta-lactamases in clinical isolates of pseudomonas aeruginosa. Diagn Microbiol Infect Dis (2004) 1.16
Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. Antimicrob Agents Chemother (2002) 1.15
Molecular evidence for broad-scale distributions in bdelloid rotifers: everything is not everywhere but most things are very widespread. Mol Ecol (2008) 1.14
Crystal structure of the narrow-spectrum OXA-46 class D beta-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob Agents Chemother (2010) 1.13
Escherichia coli ST131 producing extended-spectrum β-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clin Infect Dis (2011) 1.11
Detection of VIM-5 metallo-beta-lactamase in a Pseudomonas aeruginosa clinical isolate from Turkey. J Antimicrob Chemother (2004) 1.10
Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem (2006) 1.10
DNA microarray for detection of macrolide resistance genes. Antimicrob Agents Chemother (2006) 1.09
A late complication of pelvic radiotherapy: leiomyosarcoma of the rectum. Report of a case and review of the literature. Hepatogastroenterology (2003) 1.09
Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. Proc Natl Acad Sci U S A (2011) 1.07
Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2013) 1.06
Postgenomic scan of metallo-beta-lactamase homologues in rhizobacteria: identification and characterization of BJP-1, a subclass B3 ortholog from Bradyrhizobium japonicum. Antimicrob Agents Chemother (2006) 1.05
Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Rev Anti Infect Ther (2008) 1.05
Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 beta-lactamases. J Antimicrob Chemother (2007) 1.05
Evidence for inefficient selection against deleterious mutations in cytochrome oxidase I of asexual bdelloid rotifers. Mol Biol Evol (2007) 1.05
Antibiotic resistance in a very remote Amazonas community. Int J Antimicrob Agents (2008) 1.04
OXA-46, a new class D beta-lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother (2005) 1.04
Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey. Antimicrob Agents Chemother (2002) 1.04
Tracking acquired antibiotic resistance in commensal bacteria of Galápagos land iguanas: no man, no resistance. PLoS One (2010) 1.03
Carbapenem-resistant Pseudomonas aeruginosa-carrying VIM-2 metallo-beta-lactamase determinants, Croatia. Emerg Infect Dis (2003) 1.03
Molecular basis of branched peptides resistance to enzyme proteolysis. Chem Biol Drug Des (2007) 1.03
Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents (2008) 1.03
Novel 3-N-aminoglycoside acetyltransferase gene, aac(3)-Ic, from a Pseudomonas aeruginosa integron. Antimicrob Agents Chemother (2003) 1.02
Evaluation of the New NucliSENS EasyQ KPC test for rapid detection of Klebsiella pneumoniae carbapenemase genes (blaKPC). J Clin Microbiol (2012) 1.02
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother (2010) 1.02
Epidemiology and genetic characteristics of extended-spectrum β-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother (2012) 1.02
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. Antimicrob Agents Chemother (2009) 1.01
Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate. Antiviral Res (2010) 1.00
A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J (2009) 1.00
Mycobacterium yongonense in pulmonary disease, Italy. Emerg Infect Dis (2013) 1.00
Characteristics of clinical isolates of Acinetobacter genomospecies 10 carrying two different metallo-beta-lactamases. Int J Antimicrob Agents (2010) 1.00
Mutational analysis of the two zinc-binding sites of the Bacillus cereus 569/H/9 metallo-beta-lactamase. Biochem J (2002) 1.00
Prediction of quaternary assembly of SARS coronavirus peplomer. Biochem Biophys Res Commun (2004) 1.00
High prevalence of qnr genes in commensal enterobacteria from healthy children in Peru and Bolivia. Antimicrob Agents Chemother (2009) 0.99
Characterization of small ColE-like plasmids mediating widespread dissemination of the qnrB19 gene in commensal enterobacteria. Antimicrob Agents Chemother (2009) 0.99
Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect Immun (2003) 0.98
Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol Cancer Ther (2007) 0.98
Trehalose in desiccated rotifers: a comparison between a bdelloid and a monogonont species. Comp Biochem Physiol A Mol Integr Physiol (2004) 0.98